Citations

Clear

13603 citation(s) found for "_, _".

Abstract Tu0077: CD14 + Mononuclear Phagocyte Gene Expression is Altered in Peripheral Arterial Disease
Sawhney, Amitoj Singh , Cai, Jimmy, Schaller, Melinda S. , Cai, Jimmy, Brownfield, Douglas

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | June 23, 2025 | Volume: 45 | Issue: Suppl_1 | Pages: No page available

10.1161/atv.45.suppl_1.tu0077 Get It

Introduction: Atherosclerotic arterial disease is the leading cause of death throughout the world. One of the most advanced forms of atherosclerosis, peripheral arterial disease (PAD), affects over 8.5 million people in the United States and over 230 million globally. This disease begins from an inflammatory lesion, known as the fatty streak, formed by mononuclear phagocytes (MNPs), a broad cell type classification that includes monocytes, dendritic cells, and macrophages. Development of more efficacious treatments for PAD requires that we better understand the cellular and molecular processes by which MNPs form these inflammatory lesions. Methods: To compare gene expression of MNPs, we performed scRNAseq on PBMCs from an initial cohort of 4 patients with PAD, mild claudicants to minor tissue loss (Rutherford 1-5), and 5 healthy individuals, defined as those without any chronic diseases and a hsCRP <2.0 mg/L. We conducted single cell RNA library generation using Parse Bio and sequenced to a depth of 70k reads per cell and downstream bioinformatic and differentially gene expression analysis via R and Seurat. Results: Gene expression differences in healthy versus PAD cells were visualized on a UMAP plot. Aligning our cells to the human PBMC Cell Atlas, we found that the cell type with the greatest transcriptional change (healthy vs. PAD) was CD14 + MNPs. Next, we screened for differentially expressed genes within this CD14 + MNP cluster between healthy and PAD subjects and identified 854 upregulated and 730 downregulated genes (log 2 fold change ≥ 0.25 and p < 0.05, Welch’s t-test). Two of the most significantly upregulated genes in PAD CD14 + MNPs are FAM20A and TMTC1. FAM20A encodes a psuedokinase important in calcium homeostasis as well as bone mineralization and that is upregulated in advanced atherosclerotic plaques. TMTC1 encodes for an endoplasmic reticulum protein also involved in calcium homeostasis, vascular homeostasis, and endothelial cadherin egress. Finally, one gene we found downregulated in PAD is CD83, a molecule implicated in resolution of inflammation, that when downregulated promotes an inflammatory state. Conclusion: Based on these findings we hypothesize that in PAD there exists a distinct transcriptional program along the CD14 + MNP cell type lineage that is pro-inflammatory and that may play a role in disease progression and response to intervention.
Abstract Th0051: SIRT6 Overexpression Fails to Protect Against Age-Associated Vascular Dysfunction in Mice
Villarama, Maria, Roos, Carolyn M, Hagler, Michael A , Zhang, Bin , Smith, Leslie, Miller, Jordan D.

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | June 23, 2025 | Volume: 45 | Issue: Suppl_1 | Pages: No page available

10.1161/atv.45.suppl_1.th0051 Get It

Introduction: Previous findings suggest that sirtuin 6 (SIRT6), a nuclear histone deacetylase, is involved in fundamental processes that regulate aging, which include DNA damage repair and maintenance of genomic stability. It remains unclear, however, whether SIRT6 overexpression can mitigate age-related vascular dysfunction due to multiple mechanisms of posttranslational enzyme inactivation (oxidation, ubiquitination-dependent degradation, etc). We hypothesized that overexpression of SIRT6, will improve both endothelium-dependent relaxation and smooth muscle contractile function and improve molecular mechanisms underlying these functions in healthy aged mice. Methods: We used normocholesterolemic mice that were either wild-type for SIRT6 (WT) or overexpressing one copy of SIRT6 (TG) and studied them at either 3 or 18 months of age. We assessed molecular changes in SIRT6 expression, cellular senescence, and vascular contractile protein expression using qPCR, and aortic rings in isolated organ bath chambers to measure endothelium-dependent relaxation to acetylcholine (ACH), endothelium-independent relaxation to sodium nitroprusside (SNP), and contractile responses to serotonin (5HT) and PGF 2α . Results: As expected, overexpression of SIRT6 in TG mice resulted in ~3-fold mRNA expression increase compared to WT mice in aorta. In line with our previous reports, SIRT6 mRNA levels significantly increased with age in aorta. CDKN2A, a cellular senescence marker, increased with aging in WT mice. Surprisingly, SIRT6 overexpression did not attenuate this increase, with TG mice tending to have higher CDKN2A expression than WT at 18m. ACTA2, a contractile protein marker, had modest reductions with age in WT mice, and surprisingly, overexpression of SIRT6 did not alter ACTA2 levels compared to WT at either time point. Finally, overexpression of SIRT6 did not mitigate age-related changes in vascular relaxation or contractile function. Conclusion: Collectively, these data at the surface level suggest that overexpressing SIRT6 does not protect against conduit vessel dysfunction in aged mice and is associated with paradoxical increases in senescent cell markers. It remains elusive whether there are other molecular modulators of aging that offset or alter the activity of SIRT6 with its genetic overexpression. Therefore, future studies investigating molecular determinants of SIRT6 bioactivity and its tissue/context dependence with aging are warranted.
Abstract Th0038: Endothelial CD40 Drives EndMT-Induced Inflammation In Atherosclerosis
Dzobo, Kim E. , Shami, Annelie , Nardi, Valentina , Xiong, Yuning, Edsfeldt, Andreas , Lutgens, Esther, Nardi, Valentina , Nardi, Valentina , Nitz, Katrin , Sun, Jiangming , Gialeli, Chrysostomi , Barghouth, Mohammad , Lerman, Amir , Wang, Ying , Gonçalves, Isabel , Simons, Michael , Lutgens, Esther

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | June 23, 2025 | Volume: 45 | Issue: Suppl_1 | Pages: No page available

10.1161/atv.45.suppl_1.th0038 Get It

Introduction: Atherosclerosis, the underlying cause of cardiovascular disease (CVD), is a lipid-driven chronic inflammatory disease. We have identified the co-stimulatory CD40-CD40L immune checkpoint dyad as a key driver of inflammation during atherosclerosis. CD40 and CD40L exert cell-type divergent functions via different signaling pathways. Hypothesis: We hypothesize that CD40 on endothelial cell (ECs) induces endothelial-to-mesenchymal transition (EndMT)-mediated vascular inflammation in atherosclerosis. Methods & Results: Using single cell RNAseq, we found that CD40 (TNFRSF5) is expressed on PDE3A + GJA5 + and KDR + COL15A1 + ECs of advanced human carotid atherosclerotic plaques. CD40 is highly expressed in the endothelial lining of human and mouse atherosclerotic plaques, and colocalizes with the EndMT markers fibronectin and collagen and adhesion molecule ICAM-1. CD40L activation of human aortic endothelial cells (HAECs) results in expression of the EndMT markers fibronectin, vimentin, sm22α, FSP1 and snail. Activation of CD40 in EC induces filamin A dependent translocation of CD40 into lipid rafts, increases TNF-receptor associated factor (TRAFs) -2, -3 and 6 levels, induces Akt signaling and increases expression of VCAM1 and CCL2. Conclusions: The endothelial cell has been more and more regarded as a cell type that plays a major role in driving inflammation. Our data suggest that the CD40-CD40L axis plays a significant role in EC-mediated inflammation in atherosclerosis by driving EndMT.
Placebo‐Controlled, Randomized Double‐Blind N‐Of‐1 Trial to Study Safety and Potential Efficacy of TJ‐68 for Improving Muscle Cramps in Patients With Amyotrophic Lateral Sclerosis: A Pilot Study
Mitsumoto, Hiroshi , Oskarsson, Björn , Jang, Grace E. , Andrews, Howard , Johnson, Stephen A. , Shah, Jaimin , Fernandes, Joseph Americo, Andrews, Jinsy , Rao, Maya K., McElhiney, Martin , Oskarsson, Björn , Johnson, Stephen A , Shah, Jaimin S, Cheung, Ken , Fernandes, J. Americo

Mayo Clinic

Muscle & Nerve | June 23, 2025 | Volume: 72 | Issue: 3 | Pages: 485-492

10.1002/mus.28459 | PMID 40545904 Get It

ABSTRACTIntroduction/AimsMuscle cramps are a common symptom in amyotrophic lateral sclerosis (ALS). Ameliorating muscle cramps may improve quality of life in devastating diseases like ALS. A traditional Japanese medicine (Kampo, TJ‐68) is widely prescribed in Japan for muscle cramps. However, it is not available in the USA. This study evaluated the safety, tolerability, and efficacy of TJ‐68 in ALS.MethodsThis study was a double‐blind, randomized, placebo‐controlled crossover trial, consisting of four periods, conducted at three centers in the USA. Safety was evaluated using multiple measures. The primary efficacy outcome was the Visual Analog Scale for Muscle Cramps Affecting Overall Daily Activity (item #5 of the Muscle Cramp Scale (MCS)). The secondary outcomes included the remaining items of the MCS and the Clinical Global Impression of Changes (CGIC), among others. The study was planned to enroll 22 participants with ALS within 2 years.ResultsThe enrollment was slow and was completed with 11 participants. There were no serious safety issues and TJ‐68 was well tolerated. Although the primary outcome measure did not reach statistical significance (p = 0.35), several secondary measures showed significant results: MCS #1 triggering of cramps (p = 0.01), MCS #2 cramp frequency (p = 0.03), MCS Additional 1 change of motor behaviors (p = 0.02), and CGIC assessed by the evaluator (p = 0.009). Other outcome measures did not reach statistical significance.DiscussionThe study revealed that N‐of‐1 trial design can detect changes in a small sample size, and TJ‐68 appeared to be safe. Larger studies are needed to confirm the efficacy of TJ‐68.
International Registry of thyroid cancer in Latin American (CaTaLiNA): epidemiology, clinical and follow-up study protocol in Latin American countries during the period 2023–2028
Solís-Pazmiño, Paola , Solis-Pazmino, Paola , Ledesma, Tannya, Alvarado, Brayner Alejandro Ramírez, Rojas, Tatiana, Pazmino, Camila , Tite, Belen, Figueroa, Luis, Hernández, Víctor, Salazar, Jorge, García, Cristhian, Rosero, Daniela, Ruilova, Lisbeth, Imaicela, Luis , Abad, Hamilton, Palacios, Antonio Lozano, Zanella, Virgílio Gonzales , Nasseri, Yosef , Cohen, Jason , Brito, Juan P. , Ponce-Ponte, Oscar J., Ponce, Oscar J. , Lincango, Eddy, Rojas, Tatiana , Brito, Juan P , Ponce, Oscar Josue , Pilatuna, Eduardo A , Ron, Mario , Alvarado, Benjamin, Figueroa, Luis, Lincango-Naranjo, Eddy , Rosero, Daniela, López‐Guerrero, José Antonio , Paz‐Ibarra, José , Gonzalez, Camilo, Palacios, Antonio, Soto-Becerra, Percy

Mayo Clinic

BMJ Open | June 22, 2025 | Volume: 15 | Issue: 6 | Pages: e093471

10.1136/bmjopen-2024-093471 | PMID 40545306 Get It

Introduction Differentiated thyroid cancer (DTC) is the most common endocrine malignancy, with a high 5-year survival rate of approximately 98%. Despite advances in diagnosis and treatment, up to 20% of patients experience recurrence, adversely affecting their quality of life. Predictive models have been developed to assess recurrence risk and guide clinical decision-making, but these models often face limitations such as retrospective design, lack of diversity in study populations and absence of external validation. The primary aim is to externally validate existing predictive models for DTC recurrence using prospective data from a diverse Latin American cohort. The secondary aim is to explore opportunities for model recalibration to improve their performance in our population. Methods and analysis The CaTaLiNA study is a multicentre prospective observational study conducted across 10 hospitals in five Latin American countries, including Ecuador, Peru, Uruguay and Mexico. Patients aged 18 years or older receiving treatment for DTC, such as the first thyroid surgery, active surveillance or radiofrequency ablation will be included. Recruitment will occur from November 2023 to June 2025, with follow-up extending until June 2028. Data collection will include baseline clinical, surgical and histological characteristics, treatment details and follow-up outcomes. Statistical analysis will follow the Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis guidelines, using imputation strategies for missing data and evaluating calibration and discrimination of the prediction models. Calibration measures include the ratio of expected and observed events, calibration slope and calibration plot, while discrimination will be assessed using the C-index and area under the receiver operating characteristic curve. Ethics and dissemination This study protocol was approved by Comité de Ética de Investigación en Seres Humanos de la Universidad San Francisco de Quito USFQ ‘CEISH-USFQ’ APO-010–2023-CEIHS-USFQ Oficio No. 161-2023-CA-23030M-CEISH-USFQ. Results will be disseminated via peer-reviewed publications.
Sacral fracture risk after stereotactic spinal radiosurgery: a multi-institution, retrospective analysis
Goethe, Eric A. , Almeida, Romulo Augusto Andrade de, Mikula, Anthony L. , Merrell, Kenneth W. , Rose, Peter S. , Karim, S. Mohammed, Linzey, Joseph R. , Szerlip, Nicholas J. , Ghia, Amol J. , Li, Jing , McAleer, Mary Frances, Perni, Subha , Yeboa, D.N. , Rhines, Laurence D. , North, Robert Y. , Almeida, Rômulo Augusto Andrade de , Call-Orellana, Francisco Alfredo , Clarke, Michelle J. , Amini, Behrang , Beckham, Thomas Hendrix , Tom, Martin C. , McAleer, Mary Frances , Wang, Chenyang , Price, Anthony, Alvarez‐Breckenridge, Christopher , Tatsui, Claudio Esteves

Mayo Clinic

Journal of Neurosurgery: Spine | June 20, 2025 | Volume: 43 | Issue: 3 | Pages: 305-312

10.3171/2025.2.spine24770 | PMID 40540799 Get It

OBJECTIVE Spinal stereotactic radiosurgery (SSRS) is an established treatment modality for spinal metastatic disease. A common complication of SSRS is postradiation pathologic fracture. The authors evaluated the risk of pathologic fracture in sacral SSRS. METHODS All patients receiving SSRS in 1 to 5 fractions to 1 or more sacral levels between 2011 and 2020 at participating institutions were included. Demographic, histological, anatomical, and outcome data were obtained from electronic medical records. Data were analyzed using SPSS version 28. RESULTS Of 67 total patients, 50 (74.6%) were men and 17 (25.4%) were women. The most common tumor histologies were prostate adenocarcinoma (n = 16 [23.9%]) and renal cell carcinoma (n = 12 [17.9%]). Median (range) age at treatment was 63 (8–87) years. The mean ± SD (range) number of levels treated was 1.5 ± 0.7 (1–4) levels. Mean ± SD (range) bone density at S1 was 208.0 ± 74.4 (−3.0 to 443.3) Hounsfield units (HUs). Median (range) follow-up was 16.6 (1.5–132) months, median ± SD (range) overall survival was 24 ± 21.0 (1.7–83.3) months, and the 1-year local control rate was 83.6%. Fourteen patients (20.9%) experienced fracture within the radiation field. There was no association between fracture and patient sex (p = 0.32), age (p = 0.40), S1 HU (p = 0.28), tumor location according to Denis classification (p = 0.87), presence of pain (p = 0.66), single versus multifraction radiation (p = 0.44), or number of levels treated (p = 0.52). Patients experiencing in-field progression were more likely to experience fracture (61.5% vs 10.2%, p < 0.001), and patients experiencing fracture had a higher average Spine Instability Neoplastic Score than patients without fracture (5.7 vs 4.3, p = 0.049). Only local control remained as a factor associated with sacral fracture in the multivariate analysis. Of the patients experiencing fracture, 10 (71.4%) were symptomatic and 3 of those (30.0%) underwent post-SSRS surgical intervention. CONCLUSIONS Pathologic fracture may occur after sacral SSRS in a significant number of patients and is significantly associated with failure of local control.
Decoding the Clinical Features that Associate with Progression, Causes, and Outcomes in Patients with Suspected Rapidly Progressive Dementia
Piura, Yoav , Satyadev, Nihal , Corriveau‐Lecavalier, Nick , Kuchenbecker, Lindsey A. , Geschwind, Michael D. , Tipton, Philip W. , Graff‐Radford, Neill R., Day, Gregory S. , Piura, Yoav D , Tipton, Philip W , Day, Gregory S , Corriveau-Lecavalier, Nick , Haydu, Lauren E. , Graff‐Radford, Neill R.

Mayo Clinic

Annals of Neurology | June 20, 2025 | Volume: 98 | Issue: 4 | Pages: 764-776

10.1002/ana.27297 | PMID 40539812 Get It

Objective To determine the clinical features that identify patients with suspected rapidly progressive dementia (RPD) who will develop RPD. Methods Patients with suspected RPD were enrolled and followed at Mayo Clinic (Jacksonville, FL; January 2020 to October 2023) and Washington University (Saint Louis, MO; June 2016 to December 2019). Two dementia specialists independently reviewed clinical data and assigned diagnoses. Patients were diagnosed with RPD if they developed dementia within 1 year or incapacitation within 2 years of symptom onset. The associations between clinical features and causes and outcomes were explored via univariate and multivariate comparisons. Results Of 248 patients with suspected RPD, 185 (74.6%) met criteria for RPD. Patients with RPD were older (62.6 ± 14.5 vs 55.2 ± 18.1 years; p < 0.001), and more frequently diagnosed with Alzheimer's disease or related dementias (OR 3.13, 95% CI 1.40, 7.31) or Creutzfeldt–Jakob disease (OR 4.67, 95% CI 1.38, 15.75). Visual agnosia (15/183; 8.2%), substantial brain atrophy (27/182; 14.8%), and periodic epileptiform discharges (11/151; 7.3%) were exclusively detected in patients with RPD. After controlling for age, intensive care unit admission (OR 4.77, 95% CI 1.61, 14.12), lack of seizures (OR 2.47, 95% CI 1.15, 5.31), abnormal brain magnetic resonance imaging (OR 2.01, 95% CI 0.997, 4.05), and cerebrospinal fluid white blood cell count ≤5 cells/mm 3 (OR 3.30, 95% CI 1.60, 6.82) were also independently associated with RPD. Patients with RPD were more likely to die or develop severe dementia (mean time to outcome, 36.1 months; 95% CI 31.2–41.0). Interpretation Selected clinical features may identify patients with suspected RPD who are likely to continue to decline. Early recognition of these features may improve diagnostic accuracy and inform prognosis. ANN NEUROL 2025;98:764–776
The Relationship Between Neuromuscular Block Depth and Airway Retroglossal Area: A Prospective, Nonrandomized, Observational Clinical Trial
Asztalos, László , Boktor, Mena, Kukuly, Miklós, Sólyom, Dorka, Pongrácz, Adrienn , Brull, Sorin J. , Fülesdi, Béla , Brull, Sorin J

Mayo Clinic

Journal of Clinical Medicine | June 19, 2025 | Volume: 14 | Issue: 12 | Pages: 4374

10.3390/jcm14124374 | PMID 40566125 Get It

Background: Tracheal intubation and mechanical ventilation are facilitated by neuromuscular blocking agents. We investigated the effectiveness of subjective clinical evaluation of neuromuscular function on retroglossal area size, since it determines spontaneous ventilation adequacy following tracheal extubation. Secondarily, we correlated changes in retroglossal area and depth of neuromuscular block assessed during both respiratory phases using quantitative neuromuscular monitoring. Methods: Once mechanical ventilation was no longer needed, antagonists were used to reverse the neuromuscular block in 21 consenting patients; adequacy of reversal was assessed subjectively by delivering a sequence of four rapid (2 Hz) electrical stimuli (train-of-four, TOF) to a peripheral nerve and assessing attainment of four equal muscle contractions (TOF ratio = 1.0), signifying normal neuromuscular function. Retroglossal area during both inhalation and exhalation were measured pharyngoscopically at various phases of neuromuscular recovery, including at baseline after anesthesia induction but before neuromuscular block onset and at recovery before tracheal extubation; area changes were correlated with depth of quantitatively measured neuromuscular block. Results: Clinicians’ subjective evaluation of readiness for tracheal extubation failed to identify significant residual block in most patients who required rescue antagonism. Markedly decreased retroglossal areas (inhalation: 39.5% of baseline; exhalation: 20.1% of baseline) were present at extubation, and 11 out of 21 (52.4%) patients needed rescue antagonism. In contrast, in patients with neuromuscular recovery to the currently recommended threshold determined quantitatively (TOF ratio > 0.90), retroglossal areas were only 80% recovered but returned to near baseline values when the TOF ratio ≥ 0.95. Conclusions: Quantitative monitoring should guide the timing of tracheal extubation. Current definitions of the minimal threshold for adequate neuromuscular recovery (TOF ratio > 0.90) after mechanical ventilation in postoperative patients should be re-evaluated. A TOF ratio > 0.95 better correlates with return to normal (baseline) retroglossal area during both inhalation and exhalation.
Current Perspectives on Mesenchymal Dendritic Cell Neoplasms of Lymphoid Tissue: Insights into Ontogeny, Updates on Classification, and Clinicopathologic Characteristics
Seth, Neha , Abeykoon, Jithma P. , Tessier, Steven , King, Rebecca L. , Ravindran, Aishwarya , Ravindran, Aishwarya , Goyal, Gaurav , Go, Ronald S.

Mayo Clinic

Cancers | June 19, 2025 | Volume: 17 | Issue: 12 | Pages: 2055

10.3390/cancers17122055 | PMID 40563703 Get It

Mesenchymal dendritic cell neoplasms represent a distinct category of hematologic malignancies that challenge traditional classifications of histiocytic and classical dendritic/Langerhans cell neoplasms. Historically grouped under the broader umbrella of dendritic cell neoplasms, these entities differ significantly in their ontogeny, histopathologic features, molecular alterations, and clinical behavior. They are categorized into three main subtypes including follicular dendritic cell sarcoma, fibroblastic reticular cell tumor, and EBV-positive inflammatory follicular dendritic cell sarcoma/fibroblastic reticular cell tumor. They originate from mesenchymal stromal cells, and genetic alterations activating the NF- κβ pathway are frequent in follicular dendritic cell sarcomas. Immunophenotypic characterization is critical to distinguish these from other hematologic malignancies including histiocytic and classical dendritic/Langerhans cell neoplasms and other solid (non-hematopoietic) cancers. This review recapitulates current knowledge on existing classifications, details their diverse ontogeny from classical dendritic cell neoplasms, and provides insights into their clinicopathologic characteristics to improve diagnostic accuracy. We detail two case studies that demonstrate the challenges involved in the histopathologic diagnosis of these rare tumors, necessitating a comprehensive workup. Integrating developmental biology into practical diagnostic algorithms is essential to improve recognition and classification of these underdiagnosed neoplasms, ultimately guiding timely management.
Trafficking and Activation of Henipavirus, Parahenipavirus, and Henipa-like Virus Fusion Proteins
Navaratnarajah, Chanakha K. , Cattaneo, Roberto , Cattaneo, Roberto

Mayo Clinic

Viruses | June 19, 2025 | Volume: 17 | Issue: 6 | Pages: 866

10.3390/v17060866 | PMID 40573457 Get It

Henipaviruses are emerging zoonotic viruses that have caused deadly outbreaks in humans and livestock across several regions of the world. The fusion (F) protein of henipaviruses plays a critical role in viral entry into host cells and represents a key determinant of viral pathogenicity. This review provides a comprehensive analysis of current knowledge regarding trafficking, activation, as well as the role in particle assembly, of henipavirus F proteins. We discuss the unique characteristics of henipavirus F proteins compared to other paramyxovirus fusion proteins, with particular emphasis on their distinctive trafficking and activation mechanisms. Attention is also given to novel henipaviruses that have been detected in hosts other than bats, namely rodents and shrews. These viruses are sufficiently different that the International Committee on Taxonomy of Viruses has proposed a new genus for them, the Parahenipaviruses. We discuss how variations in F protein characteristics between Henipaviruses, Parahenipaviruses, and yet-unclassified henipa-like viruses might influence their trafficking and activation. Understanding these molecular mechanisms is crucial for developing effective therapeutic strategies against henipavirus infections and for predicting the emergence of novel henipavirus strains with pandemic potential.